期刊文献+

阿托伐他汀对进展性脑梗死进展时间及神经功能的影响 被引量:27

Effect of atorvastatin on progressive cerebral infarction time and nerve function
下载PDF
导出
摘要 目的探讨阿托伐他汀对进展性脑梗死进展时间及神经功能缺损程度的影响。方法选取2005-01~2008-12住院的进展性脑梗死86例,随机分为治疗组和对照组各43例,对照组:NS 250 ml+奥扎格雷针80 mg,1次/d静滴,NS250ml+复方丹参针20ml,1次/d静滴,NS 250ml(或5%GS 250ml)+胞磷胆碱针0.75g 1次/d静滴,低分子肝素钙针5000U,1次/12h,皮下注射,连用5d。治疗组在对照组基础上加用阿托伐他汀片20mg,入院后立即口服,继而1次/d口服,连用4周。观察入院时、进展停止时、发病4周时神经功能缺损程度和发病至症状达高峰时间。结果2组在发病至症状达峰时间、发病4周时NIHSS评分方面差异均有统计学意义。结论进展性脑梗死应用阿托伐他汀安全,可改善预后。 Objective To investigate the effect of atorvastatin on progressive cerebral infarction ment time and lack of nerve function. Methods From January 2005 to December 2008, 86 cases were randomly divided into treat ment group of 43 cases and control group of 43 cases. Control group: NS 250 ml+ augerneanapin 80 rag, one time intravenous drip each day, NS 250 ml + danshen 20 ml, one time intravenous drip each day, NS 250 ml(or 5% GS 250 ml )+ citicoline 0.75g, one time intravenous drip each day, LMWH 5000U, 12 h each time, subcutaneous (or hypodermic) injection, continu onsly using 5 days. Treatment group should plus use atorvastatin 20 mg on the basis of control group while in hospital and continuously usingfor 4 weeks. The influences of degree of nervous functional defects and symptom up to peak time were observed. Results The two groups had the significant difference on grade of NIHSS while onset, up to peak time. Conclusion Atorvastatin on progressive cerebral infarction is safe, and could improve the prognosis.
出处 《中国实用神经疾病杂志》 2010年第1期22-24,共3页 Chinese Journal of Practical Nervous Diseases
关键词 进展性脑梗死 阿托伐他汀 神经功能缺损程度 预后 Progressive cerebral infarction Atorvastatin Degree of nervous functional defects Prognosis
  • 相关文献

参考文献8

二级参考文献42

  • 1曹红,孙长凯,赵杰,赵耿毅,唐树良,汪秋艳,侯宇,许晶,陶定波,刘新胜,黄爱莉.他汀类药物对脑梗死患者神经功能缺损及血清相关参数的影响[J].中国临床康复,2005,9(9):94-96. 被引量:25
  • 2Dziedzic T,Gryz EA,Turaj W,et al.Serum interleukin-6 soluble receptor in relation to interleukin-6 in stroke patients[J].J Mol Neurosci,2004,24:293-298.
  • 3Silvestri A,Vitale C,Ferretti F,et al.Plasma levels of inflammatory C-reactive protein and interleukin-6 predict outcome in elderly patients with stroke[J].J Am Geriatr Soc,2004,52:1586-1587.
  • 4Muir KW,Weir CJ,Alwan W,et al.C-reactive protein and outcome after ischemic stroke[J].Stroke,1999,30:981-985.
  • 5Lee KT,Lai WT,Chu CS,et al.Effect of withdrawal of statin on Creactive protein[J].Cardiology,2004,102:166-170.
  • 6VaughanCJ,Delanty N,Basson CT.Statin therapy and stroke prevention[J].Curr Opin Cardiol,2001,16:219-224.
  • 7Endres M,Laufs U,Huang Z,et al.Stroke protection by 3-hydroxy3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase[J].Proc Natl Acad Sci USA,1998,95:8880-8885.
  • 8Vaughan C J,Delanty N,Basson CT. Do statins afford neuroprotection in patients with cerebral ischaemia and stroke? CNS Drugs 2001; 15:589 - 96.
  • 9Vaughan C J,Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999; 30:1969 -73.
  • 10Sawada N,Itoh H,Nakao K. Novel actions of HMG-CoA reductase inhibitors(statins) -vascular and cerebral protection through inhibition of small GTPase Rho. Nippon Rinsho 2001;59:2470-5.

共引文献77

同被引文献148

二级引证文献206

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部